These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 15887014)

  • 1. T cell-mediated graft-versus-leukemia reactions after allogeneic stem cell transplantation.
    Schetelig J; Kiani A; Schmitz M; Ehninger G; Bornhäuser M
    Cancer Immunol Immunother; 2005 Nov; 54(11):1043-58. PubMed ID: 15887014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation.
    Rezvani K; Barrett AJ
    Best Pract Res Clin Haematol; 2008 Sep; 21(3):437-53. PubMed ID: 18790448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.
    van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM
    Front Immunol; 2020; 11():1804. PubMed ID: 32973756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minor histocompatibility antigens as targets of graft-versus-leukemia reactions.
    Falkenburg JH; Marijt WA; Heemskerk MH; Willemze R
    Curr Opin Hematol; 2002 Nov; 9(6):497-502. PubMed ID: 12394171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant.
    Weber G; Gerdemann U; Caruana I; Savoldo B; Hensel NF; Rabin KR; Shpall EJ; Melenhorst JJ; Leen AM; Barrett AJ; Bollard CM
    Leukemia; 2013 Jul; 27(7):1538-47. PubMed ID: 23528871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
    Fowler DH; Gress RE
    Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of minor histocompatiblity antigen HA-1-specific cytotoxic T cells for the treatment of leukemia after allogeneic stem cell transplantation.
    Brossart P; Spahlinger B; Grünebach F; Stuhler G; Reichardt VL; Kanz L; Brugger
    Blood; 1999 Dec; 94(12):4374-6. PubMed ID: 10636695
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens.
    Warren EH; Fujii N; Akatsuka Y; Chaney CN; Mito JK; Loeb KR; Gooley TA; Brown ML; Koo KK; Rosinski KV; Ogawa S; Matsubara A; Appelbaum FR; Riddell SR
    Blood; 2010 May; 115(19):3869-78. PubMed ID: 20071660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
    Chang YJ; Zhao XY; Huang XJ
    Front Immunol; 2018; 9():3041. PubMed ID: 30619371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Minor antigens - major impact. The role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation].
    Hudecek M; Bartsch K; Tschiedel S; Niederwieser D
    Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1511-6. PubMed ID: 18597211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Ishikawa T; Fujii N; Imada M; Aoe M; Meguri Y; Inomata T; Nakashima H; Fujii K; Yoshida S; Nishimori H; Matsuoka KI; Kondo E; Maeda Y; Tanimoto M
    Cytotherapy; 2017 Apr; 19(4):514-520. PubMed ID: 28139337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells.
    Young FM; Campbell A; Emo KL; Jansson J; Wang PY; Jordan CT; Mullen CA
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):622-30. PubMed ID: 18489987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation.
    Riddell SR; Berger C; Murata M; Randolph S; Warren EH
    Blood Rev; 2003 Sep; 17(3):153-62. PubMed ID: 12818225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1.
    Oostvogels R; Minnema MC; van Elk M; Spaapen RM; te Raa GD; Giovannone B; Buijs A; van Baarle D; Kater AP; Griffioen M; Spierings E; Lokhorst HM; Mutis T
    Leukemia; 2013 Mar; 27(3):642-9. PubMed ID: 23079962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation.
    Liu J; Zhang X; Zhong JF; Zhang C
    Immunotherapy; 2019 Jan; 11(1):37-44. PubMed ID: 30702011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimized Whole Genome Association Scanning for Discovery of HLA Class I-Restricted Minor Histocompatibility Antigens.
    Fuchs KJ; Honders MW; van der Meijden ED; Adriaans AE; van der Lee DI; Pont MJ; Monajemi R; Kielbasa SM; 't Hoen PAC; van Bergen CAM; Falkenburg JHF; Griffioen M
    Front Immunol; 2020; 11():659. PubMed ID: 32362897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of leukemia relapse after allogeneic hematopoietic stem cell transplantation: integrating transplantation with genetically modified T cell therapies.
    Dotti G
    Curr Opin Hematol; 2015 Nov; 22(6):489-96. PubMed ID: 26335421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
    Tykodi SS; Warren EH; Thompson JA; Riddell SR; Childs RW; Otterud BE; Leppert MF; Storb R; Sandmaier BM
    Clin Cancer Res; 2004 Dec; 10(23):7799-811. PubMed ID: 15585611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens.
    Mutis T; Verdijk R; Schrama E; Esendam B; Brand A; Goulmy E
    Blood; 1999 Apr; 93(7):2336-41. PubMed ID: 10090944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell therapy of leukemia.
    Riddell SR; Murata M; Bryant S; Warren EH
    Cancer Control; 2002; 9(2):114-22. PubMed ID: 11965232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.